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Introduction: Colorectal cancer (CRC) is the most abundant type of neoplasia 
in developed countries and the second cause of death among cancers due mainly to 
a late diagnosis. Cancer proteins elicit an immune response in the host. Then, the 
autoantibody repertoire from cancer patients might serve to identify tumour-associated 
antigens (TAAs) that could be used as biomarkers for diagnosis and prognosis.
Experimental procedures: Protoarray was used to identify TAAs as potential 
biomarkers using 8 serums from normal individuals and 12 colorectal cancer patients. 
Western blotting analysis with seven CRC cell lines and normal and tumoral tissue 
extracts was performed with antibodies against 3 differentially expressed TAAs. 
A specific CRC tissue microarray was tested with an antibody against one of these 
differentially expressed proteins. Thirty-five serum from colorectal cancer patients and 
23 from healthy individuals were tested by ELISA with 4 purified antigens.
Results: A preliminary autoantibody signature specific for CRC has been identified. 
We have verified by immunoblotting the differential reactivity of three of those proteins. 
Pim1 and MAPKAPK3 were more abundant in tumoral samples, whereas ACVR2B 
was decreased. We have also validated by tissue microarray the absence of ACVR2B 
in colon tumoral samples. Finally, to determine the discrimination capacity between 
normal and tumoral groups, we tested 58 serum samples by ELISA using the purified 
antigens and constructed the ROC curves. Applying statistical models, the combination 
of Pim1 and ACVR2B exhibited a specificity and sensitivity of 71,4% and 77,1% to 
discriminate between groups.
Conclusions: Protein microarrays as novel high-throughput proteomic approaches 
have accelerated the interest in human serum autoantibodies against cancers for the 
discovery of candidate TAAs to be used as specific tools to diagnose cancer. We 
have identified a set of potential biomarkers for CRC diagnosis and also as potential 
immunological therapeutic targets that is being currently evaluated.
